- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00120601
Trial for the Treatment of Alcohol Dependence
July 15, 2005 updated by: University of Sydney
The Role of Pharmacotherapy in Prevention of Relapse in Alcohol Dependence
The purpose of this study is to compare the effectiveness of two anti-craving medications, naltrexone versus acamprosate, in the treatment of alcohol dependence.
Study Overview
Detailed Description
The physical, psychological and social consequences of alcohol abuse remain a critical health problem.
Every year in Australia, excessive consumption is responsible for 3,000 - 6,000 deaths and costs the community $6 billion.
Approximately 15% of Australians abuse alcohol and 5% of men and 3% of women are alcohol dependent (addicted to alcohol).
Better treatment for alcohol dependence is urgently needed.
Treatment for alcohol dependence remains unsatisfactory.
Most treatments lead to abstinence in only 1 out of 3 cases, and approximately 50% of these will relapse within 3 months of completing treatment.
Two drugs (naltrexone and acamprosate) appear to interfere with the effects of alcohol on the brain that promote addiction.
There is evidence that both drugs are beneficial in the treatment of alcohol dependence and both are now available in Australia.
At present, no data have been reported comparing the effectiveness of these two drugs.
The proposed project will compare naltrexone and acamprosate in a large, carefully performed, study.
The study will help determine which subjects are likely to benefit from one or the other of these agents.
Study Type
Interventional
Enrollment
200
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2050
- Drug Health Services, Royal Prince Alfred Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Alcohol dependence according to the ICD10 criteria, with alcohol as the subject's drug of choice
- Ages 18-65
- Adequate cognition and English language skills to give valid consent and complete research interviews (as assessed by MMSE)
- Willingness to give written informed consent
- Abstinence from alcohol for between 3 and 21 days, and resolution of any clinically evident alcohol withdrawal
Exclusion Criteria:
- Opiate abuse within the last one month
- Sensitivity to study medications or therapy with these drugs within 6 months
- Active major psychiatric disorder associated with psychosis or significant suicide risk
- Pregnancy or lactation
- Advanced decompensated liver disease (hepatocellular failure, variceal bleeding, ascites or encephalopathy)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Time (days) to relapse
|
Time (days) to lapse
|
Days abstinence
|
Drinks per drinking day
|
Biochemical measures of liver function
|
Secondary Outcome Measures
Outcome Measure |
---|
Depression
|
Anxiety
|
Craving
|
Stress
|
Global physical health
|
Global mental health
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Paul Haber, MBBAMDFRACP, Conjoint Associate Professor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2003
Study Completion
June 1, 2005
Study Registration Dates
First Submitted
July 11, 2005
First Submitted That Met QC Criteria
July 15, 2005
First Posted (Estimate)
July 18, 2005
Study Record Updates
Last Update Posted (Estimate)
July 18, 2005
Last Update Submitted That Met QC Criteria
July 15, 2005
Last Verified
June 1, 2005
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- X99-0277
- 211177
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcoholism
-
Yale UniversityCompletedFamilial Alcoholism VulnerabilityUnited States
-
Yonsei UniversityTerminated
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingFamilial Alcoholism VulnerabilityUnited States
-
University of Southern DenmarkActive, not recruitingGeneral Practice | Alcohol Abuse Alcoholism | Screening and Brief InterventionDenmark
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedEffects of Family History of Alcoholism and Sex on Alcohol AnalgesiaUnited States
-
Brown UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcoholic Liver Disease | Alcoholism,United States
-
Khoo Teck Puat HospitalNot yet recruitingEmergencies | Alcohol Use Disorder | Alcoholism and Alcohol Abuse
-
National Institute on Drug Abuse (NIDA)The Peter G. Dodge Foundation (PGDF)Completed
-
Virginia Commonwealth UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Yale University; University...CompletedAlcoholismUnited States
-
University of Sao PauloCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsEnrolling by invitation
Clinical Trials on Naltrexone
-
San Diego State UniversityRecruitingPlacebo | NaltrexoneUnited States
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem DrinkingUnited States
-
Alkermes, Inc.Terminated
-
Alkermes, Inc.Completed
-
Alkermes, Inc.Completed
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA); St. Petersburg State Pavlov Medical...CompletedOpioid-Related Disorders | Heroin DependenceUnited States, Russian Federation
-
Centre for Addiction and Mental HealthUnknown
-
Drug Delivery Company, LLC DBA Akyso PharmaceuticalsNational Institute on Drug Abuse (NIDA); Laboratory Corporation of America; Cognitive...Not yet recruiting
-
State University of New York - Upstate Medical...CephalonCompletedAlcohol Dependence | Schizophrenia | Schizoaffective Disorders | Bipolar DisordersUnited States
-
Medical University of LublinRecruitingQuality of Life | Vulvodynia | NaltrexonePoland